{"success":true,"data":{"pressRelease":{"id":"125234","rtpr_id":"nPn1LzzyHa","ticker":"REPL","exchange":"NASDAQ","all_tickers":["REPL"],"title":"Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action","author":"PR Newswire","published_at":"2026-08-21T20:20:00.028Z","article_body":"Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action\n\nPR Newswire\n\nSAN DIEGO, Aug. 21, 2026\n\nSAN DIEGO, Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins\nLLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=2700057331&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=Robbins+LLP)\n reminds investors that a class action was filed on behalf of all persons and\nentities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ:\nREPL) securities between October 20, 2025 and April 10, 2026 (\"Class Period\").\nReplimune purports to be a clinical-stage biotechnology company focused on\nnovel oncolytic immunotherapies. According to the complaint, the Company's\nlead product candidate is RP1 (vusolimogene oderparepvec).\n\nThe lawsuit alleges that the Company misled investors regarding the efficacy\nand viability of its lead product candidate RP1.\n\nIf you purchased or otherwise acquired REPL securities during the applicable\nClass Period and suffered a loss, you may have legal rights. Contact\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=1546125072&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=Contact)\n Robbins LLP for information about becoming lead plaintiff before the October\n5, 2026 deadline.\n\nWhy Was Replimune Sued?\n\nOn October 20, 2025, Replimune announced that the U.S. Food and Drug\nAdministration (\"FDA\") had accepted the resubmission of the Biologics License\nApplication (\"BLA\") for RP1 in combination with nivolumab for the treatment of\nadvanced melanoma in patients who progress on an anti-PD-1 containing regimen.\nThe Company claimed that \"[a]dditional information, data and analyses were\nincluded in the resubmission which will be part of the BLA review.\" The\nCompany also stated that \"[t]he FDA indicated this resubmission is considered\nto be a complete response to the complete response letter received in July\n2025.\"\n\nThe complaint alleges that defendants failed to disclose to investors:\n\n(1) that in connection with the BLA, the study design concerns previously\ncommunicated by the FDA were not addressed;\n\n(2) that the Company had submitted data from an early unplanned analysis from\nRP1-104, which included only 40 patients (10% of the planned enrollment of 400\npatients);\n\n(3) that, as a result, RPL-001-16 and RP1-104 both had deficiencies which were\nlikely to cause the FDA to reject the BLA; and\n\n(4) that, as a result, defendants' positive statements about the Company's\nbusiness, operations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWhy Did REPL Stock Drop?\n\nThe complaint alleges that on April 10, 2026, during market trading, the FDA\npublished a Complete Response Letter (\"CRL\") rejecting Replimune's BLA for RP1\nin combination with nivolumab. The FDA identified several deficiencies for\neach of the studies—RPL-001-16 (IGNYTE) and RP1-104 (IGNYTE-3)—submitted\nby Replimune and found that \"the evidence as presented does not meet the\nevidentiary standards required for regulatory approval, and the results of the\nadditional exploratory analyses of the RPL-001-16 data do not alter our\ninitial conclusion that the RPL-001-16 trial is not an adequate and\nwell-controlled clinical investigation that demonstrates substantial evidence\nof effectiveness.\"\n\nThe FDA further revealed that \"[t]o support resubmission of the BLA on October\n9, 2025, [Replimune] provided [objective response rate] data from an early\nunplanned analysis\" from RP1-104 which included only 40 patients, 10% of the\nplanned enrollment of 400 patients.\n\nIn the CRL, the FDA further revealed that it had \"clearly communicated\" its\n\"concerns with the study design in multiple FDA interactions throughout\n[Replimune's] development program,\" but that \"the study design concerns\npreviously communicated were not addressed, and the contribution of [RP1] to\nthe observed response rate in RPL-001-16 could not be determined.\"\n\nOn this news, the Company's share price fell $1.15 or 19.46%, before trading\nwas halted, to close at $4.76 per share on April 10, 2026, on unusually heavy\ntrading volume.\n\nThe complaint continues that on April 10, 2026, after the market closed, the\nCompany issued a press release discussing the FDA's response letter for the\nRP1 BLA. In the press release, Replimune conceded that \"a randomized\ncontrolled trial was preferred\" by the FDA, but also claimed that the FDA\ncommunicated that \"if the data was sufficiently compelling, a single arm trial\ncould be acceptable for consideration under accelerated approval.\"\n\nOn this news, the Company's share price continued to fall $3.06 or 64.29%, to\nclose at $1.70 per share on April 13, 2026.\n\nWho May Be Eligible to Participate in the Replimune Class Action?\n\nInvestors who purchased or otherwise acquired REPL securities between October\n20, 2025 and April 10, 2026, may be eligible to participate in the proposed\nsecurities class action. If you purchased REPL shares during the Class Period\nand suffered losses, you may have rights under the federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a representative investor appointed by the court to act\non behalf of other members of the proposed class and help direct the\nlitigation. Investors do not have to become lead plaintiff to potentially\nparticipate in any recovery obtained through the litigation.\n\nStockholders who wish to seek appointment as lead counsel must submit their\npapers to the court by October 5, 2026.\n\nDoes it Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis. Investors\nnever pay attorneys' fees or litigation expenses. If there is a recovery for\nshareholders, defendants pay fees and expenses.\n\nListen to our podcast\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=3170041571&u=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3De9iQX3ysMgY&a=podcast)\n.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Replimune Group Inc.\nsecurities class action may submit an inquiry\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=2698901794&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=submit+an+inquiry)\n, email (mailto:adumas@robbinsllp.com)  attorney Aaron Dumas, Jr., or call\n(800) 350-6003.\n\nAbout Robbins LLP\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=3410985298&u=https%3A%2F%2Frobbinsllp.com%2F&a=Robbins+LLP)\n has helped restore more than $1 billion in value to shareholders and secured\nsome of the largest recoveries in shareholder derivative litigation history.\n\n\"Behind everything we do is the belief that companies should be governed\nresponsibly, fiduciaries should be held accountable, and shareholders deserve\ntransparency and fairness,\" said Brian J. Robbins, Founding Partner of Robbins\nLLP.\n\nTo be notified if a class action against Replimune Group Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=1817570284&u=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&a=Stock+Watch)\n today.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/robbins-llp-urges-repl-investors-who-lost-money-investing-in-replimune-to-contact-the-firm-for-information-about-leading-the-class-action-302857491.html\n(https://www.prnewswire.com/news-releases/robbins-llp-urges-repl-investors-who-lost-money-investing-in-replimune-to-contact-the-firm-for-information-about-leading-the-class-action-302857491.html)\n\nSOURCE Robbins LLP\n\n\n\nAaron Dumas, Jr., Robbins LLP, 5060 Shoreham Pl., Ste. 300, San Diego, CA 92122, adumas@robbinsllp.com, (800) 350-6003, www.robbinsllp.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS559099/Robbins-LLP-Logo.jpg?id=OA2902759\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn1LzzyHa","title":"Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action","author":"PR Newswire","ticker":"REPL","created":"2026-08-21T20:20:00.028Z","tickers":["REPL"],"exchange":"NASDAQ","article_body":"Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action\n\nPR Newswire\n\nSAN DIEGO, Aug. 21, 2026\n\nSAN DIEGO, Aug. 21, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins\nLLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=2700057331&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=Robbins+LLP)\n reminds investors that a class action was filed on behalf of all persons and\nentities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ:\nREPL) securities between October 20, 2025 and April 10, 2026 (\"Class Period\").\nReplimune purports to be a clinical-stage biotechnology company focused on\nnovel oncolytic immunotherapies. According to the complaint, the Company's\nlead product candidate is RP1 (vusolimogene oderparepvec).\n\nThe lawsuit alleges that the Company misled investors regarding the efficacy\nand viability of its lead product candidate RP1.\n\nIf you purchased or otherwise acquired REPL securities during the applicable\nClass Period and suffered a loss, you may have legal rights. Contact\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=1546125072&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=Contact)\n Robbins LLP for information about becoming lead plaintiff before the October\n5, 2026 deadline.\n\nWhy Was Replimune Sued?\n\nOn October 20, 2025, Replimune announced that the U.S. Food and Drug\nAdministration (\"FDA\") had accepted the resubmission of the Biologics License\nApplication (\"BLA\") for RP1 in combination with nivolumab for the treatment of\nadvanced melanoma in patients who progress on an anti-PD-1 containing regimen.\nThe Company claimed that \"[a]dditional information, data and analyses were\nincluded in the resubmission which will be part of the BLA review.\" The\nCompany also stated that \"[t]he FDA indicated this resubmission is considered\nto be a complete response to the complete response letter received in July\n2025.\"\n\nThe complaint alleges that defendants failed to disclose to investors:\n\n(1) that in connection with the BLA, the study design concerns previously\ncommunicated by the FDA were not addressed;\n\n(2) that the Company had submitted data from an early unplanned analysis from\nRP1-104, which included only 40 patients (10% of the planned enrollment of 400\npatients);\n\n(3) that, as a result, RPL-001-16 and RP1-104 both had deficiencies which were\nlikely to cause the FDA to reject the BLA; and\n\n(4) that, as a result, defendants' positive statements about the Company's\nbusiness, operations, and prospects were materially misleading and/or lacked a\nreasonable basis.\n\nWhy Did REPL Stock Drop?\n\nThe complaint alleges that on April 10, 2026, during market trading, the FDA\npublished a Complete Response Letter (\"CRL\") rejecting Replimune's BLA for RP1\nin combination with nivolumab. The FDA identified several deficiencies for\neach of the studies—RPL-001-16 (IGNYTE) and RP1-104 (IGNYTE-3)—submitted\nby Replimune and found that \"the evidence as presented does not meet the\nevidentiary standards required for regulatory approval, and the results of the\nadditional exploratory analyses of the RPL-001-16 data do not alter our\ninitial conclusion that the RPL-001-16 trial is not an adequate and\nwell-controlled clinical investigation that demonstrates substantial evidence\nof effectiveness.\"\n\nThe FDA further revealed that \"[t]o support resubmission of the BLA on October\n9, 2025, [Replimune] provided [objective response rate] data from an early\nunplanned analysis\" from RP1-104 which included only 40 patients, 10% of the\nplanned enrollment of 400 patients.\n\nIn the CRL, the FDA further revealed that it had \"clearly communicated\" its\n\"concerns with the study design in multiple FDA interactions throughout\n[Replimune's] development program,\" but that \"the study design concerns\npreviously communicated were not addressed, and the contribution of [RP1] to\nthe observed response rate in RPL-001-16 could not be determined.\"\n\nOn this news, the Company's share price fell $1.15 or 19.46%, before trading\nwas halted, to close at $4.76 per share on April 10, 2026, on unusually heavy\ntrading volume.\n\nThe complaint continues that on April 10, 2026, after the market closed, the\nCompany issued a press release discussing the FDA's response letter for the\nRP1 BLA. In the press release, Replimune conceded that \"a randomized\ncontrolled trial was preferred\" by the FDA, but also claimed that the FDA\ncommunicated that \"if the data was sufficiently compelling, a single arm trial\ncould be acceptable for consideration under accelerated approval.\"\n\nOn this news, the Company's share price continued to fall $3.06 or 64.29%, to\nclose at $1.70 per share on April 13, 2026.\n\nWho May Be Eligible to Participate in the Replimune Class Action?\n\nInvestors who purchased or otherwise acquired REPL securities between October\n20, 2025 and April 10, 2026, may be eligible to participate in the proposed\nsecurities class action. If you purchased REPL shares during the Class Period\nand suffered losses, you may have rights under the federal securities laws.\n\nWhat Is a Lead Plaintiff?\n\nThe lead plaintiff is a representative investor appointed by the court to act\non behalf of other members of the proposed class and help direct the\nlitigation. Investors do not have to become lead plaintiff to potentially\nparticipate in any recovery obtained through the litigation.\n\nStockholders who wish to seek appointment as lead counsel must submit their\npapers to the court by October 5, 2026.\n\nDoes it Cost Anything to Participate?\n\nNo. Robbins LLP represents investors on a contingency fee basis. Investors\nnever pay attorneys' fees or litigation expenses. If there is a recovery for\nshareholders, defendants pay fees and expenses.\n\nListen to our podcast\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=3170041571&u=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3De9iQX3ysMgY&a=podcast)\n.\n\nContact Robbins LLP\n\nInvestors seeking additional information about the Replimune Group Inc.\nsecurities class action may submit an inquiry\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=2698901794&u=https%3A%2F%2Frobbinsllp.com%2Freplimune-group%2F&a=submit+an+inquiry)\n, email (mailto:adumas@robbinsllp.com)  attorney Aaron Dumas, Jr., or call\n(800) 350-6003.\n\nAbout Robbins LLP\n\nA recognized leader in shareholder rights litigation, Robbins LLP\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=3410985298&u=https%3A%2F%2Frobbinsllp.com%2F&a=Robbins+LLP)\n has helped restore more than $1 billion in value to shareholders and secured\nsome of the largest recoveries in shareholder derivative litigation history.\n\n\"Behind everything we do is the belief that companies should be governed\nresponsibly, fiduciaries should be held accountable, and shareholders deserve\ntransparency and fairness,\" said Brian J. Robbins, Founding Partner of Robbins\nLLP.\n\nTo be notified if a class action against Replimune Group Inc. settles or to\nreceive free alerts when corporate executives engage in wrongdoing, sign up\nfor Stock Watch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4757430-1&h=1817570284&u=https%3A%2F%2Frobbinsllp.com%2Fstock-watch%2F&a=Stock+Watch)\n today.\n\nAttorney Advertising. Past results do not guarantee a similar outcome.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/robbins-llp-urges-repl-investors-who-lost-money-investing-in-replimune-to-contact-the-firm-for-information-about-leading-the-class-action-302857491.html\n(https://www.prnewswire.com/news-releases/robbins-llp-urges-repl-investors-who-lost-money-investing-in-replimune-to-contact-the-firm-for-information-about-leading-the-class-action-302857491.html)\n\nSOURCE Robbins LLP\n\n\n\nAaron Dumas, Jr., Robbins LLP, 5060 Shoreham Pl., Ste. 300, San Diego, CA 92122, adumas@robbinsllp.com, (800) 350-6003, www.robbinsllp.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS559099/Robbins-LLP-Logo.jpg?id=OA2902759\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-08-21T20:20:00.084960976Z","server_sent_at_ms":1787343600084},"received_at":"2026-08-21T20:20:00.136Z","source_url":"https://www.prnewswire.com/news-releases/robbins-llp-urges-repl-investors-who-lost-money-investing-in-replimune-to-contact-the-firm-for-information-about-leading-the-class-action-302857491.html"},"analysis":{"id":"114187","press_release_id":"125234","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Robbins LLP issued a shareholder-solicitation notice urging REPL investors to serve as lead plaintiff in a class action concerning securities purchased between October 20, 2025 and April 10, 2026.\n\nThe complaint alleges Replimune misled investors regarding the efficacy of its lead candidate RP1 after the FDA issued a Complete Response Letter rejecting the related Biologics License Application.\n\nThis is a law-firm marketing communication, not an issuer disclosure, and serves as a routine reminder for the October 5, 2026 lead plaintiff deadline.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Behind everything we do is the belief that companies should be governed responsibly, fiduciaries should be held accountable, and shareholders deserve transparency and fairness","namedEntities":{"people":[{"name":"Aaron Dumas, Jr.","role":"Attorney"},{"name":"Brian J. Robbins","role":"Founding Partner"}],"products":["RP1","vusolimogene oderparepvec","nivolumab"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Replimune Group, Inc.","ticker":"REPL"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Robbins LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"REPL"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Robbins LLP issued a shareholder-solicitation notice urging REPL investors to serve as lead plaintiff in a class action concerning securities purchased between October 20, 2025 and April 10, 2026.\n\nThe complaint alleges Replimune misled investors regarding the efficacy of its lead candidate RP1 after the FDA issued a Complete Response Letter rejecting the related Biologics License Application.\n\nThis is a law-firm marketing communication, not an issuer disclosure, and serves as a routine reminder for the October 5, 2026 lead plaintiff deadline.","key_figures":{},"named_entities":{"people":[{"name":"Aaron Dumas, Jr.","role":"Attorney"},{"name":"Brian J. Robbins","role":"Founding Partner"}],"products":["RP1","vusolimogene oderparepvec","nivolumab"],"companies":[{"name":"Robbins LLP","relationship":"plaintiff law firm"},{"name":"Replimune Group, Inc.","ticker":"REPL"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-21T20:21:25.581Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":85425,"modelName":"glm-4.7"}}